Patients who have switched statins should receive special care as they are substantially less likely to be compliant and remain on the treatment long enough to obtain its full benefits, researchers reported in the American Journal of Managed Care.
Patients who have switched statins should receive special care as they are substantially less likely to be compliant and remain on the treatment long enough to obtain its full benefits, researchers reported in the American Journal of Managed Care.
Their conclusion was based on a retrospective database analysis consisting of 38,866 new statin users, aged 18 to 65 years, who were beginning treatment with atorvastatin, fluvastatin, lovastatin, pravastatin, or simvastatin. The data were provided by a large pharmacy benefit manager (PBM) through its pharmacy claims.
Patients who had switched statins were less compliant by 18.9% (OR, 0.81; P<.001), as defined by the probability of having a medication possession ratio (MPR) of 0.8 or higher. They also were less persistent by 20.9% to 48.3% (P<.001), depending on the gap length used to define discontinuation.
Of the 38,866 patients included in the study sample, 8.4% (n=3,248) switched drugs during their first year of treatment. The others (n=35,618) continued taking their initial drug throughout follow-up or stopped statin treatment completely.
The observed difference in persistence between switchers and nonswitchers for a 30-day gap in treatment increased from 34.6% at 6 months to 44.2% at 1 year. This resulted in part because the proportion of switchers increased with the length of time from the initial prescription; at 6 months, only 56.5% of the switchers had changed their statin treatment.
"If the switch is detrimental to persistence, we should observe a widening gap between switchers and nonswitchers," the researchers stated. "This is precisely what happens, with the odds of discontinuation within a year being at least 25% greater than within the first 6 months."
In addition, most switchers filled 4 or more prescriptions (based on an MPR level of ≥0.4).
"This level of compliance is to be expected because switchers need to be sufficiently motivated to stay on treatment long enough to undergo a change in therapy," the authors stated. "Those who lack this minimum level of motivation and consider stopping treatment after 1 or 2 prescriptions are unlikely to try a different statin."
Nonetheless, the mean MPR and the likelihood of compliance and persistence were lower for switchers than nonswitchers, "lending support to the idea that compliance drops after switching drugs," the authors noted.
Switchers were less likely to increase the dosage of their initial prescription; in turn, they reduced their out-of-pocket cost per prescription by $1.33 on average.
"The decision to switch drugs does not appear to be motivated by cost considerations," the researchers stated. "Patients who switched to a new drug saved $1.33 per prescription on average, which is too small an amount to act as a significant incentive for most patients."
The researchers stressed that their study consisted of continuously eligible commercially insured patients and did not reflect prescription utilization patterns of specific populations, such as retirees or patients transitioning between employer-sponsored insurance plans.
SOURCE Thiebaud T, Patel BV, Nichol MB, Berenbeim DM. The effect of switching on compliance and persistence: the case of statin treatment. Am J Managed Care. 2005;11:670–674.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.